Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2025-12-25 @ 10:37 PM
NCT ID: NCT00947167
Description: We followed patients until death
Frequency Threshold: 0
Time Frame: 4 years
Study: NCT00947167
Study Brief: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Pertuzumab and Erlotinib pertuzumab: 840 mg, 420 mg, iv erlotinib: 150 mg, PO None None 0 4 4 4 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Hemoglobin SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (3.0) View
Leukocytes SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (3.0) View
Platelets SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders CTCAE (3.0) View
Fatigue SYSTEMATIC_ASSESSMENT General disorders CTCAE (3.0) View
Sweating SYSTEMATIC_ASSESSMENT General disorders CTCAE (3.0) View
Hair loss SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders CTCAE (3.0) View
Rash SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders CTCAE (3.0) View
Anorexia SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Diarrhea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Mucositis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Taste SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Hemorrhage SYSTEMATIC_ASSESSMENT Gastrointestinal disorders CTCAE (3.0) View
Albumin low SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Alkaline Phosphatase elevation SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
ALT elevation SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
AST elevation SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Calcium low SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View
Potassium low SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders CTCAE (3.0) View